A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4)

Stem Cell Transplant Complications Clinical Trial

— BOSTON-4  

Official title:

A Phase IIa Multi-Center, Randomized, Single-Blind Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04107675
• Other study ID #: BT - L-CsA - 201 - SCT
• Secondary ID: 2019-000718-13
• Status: Terminated
• Phase: Phase 2
• Start date: February 11, 2020
• Est. completion date: December 15, 2022

Study information

• Verified date: September 2023
• Source: Zambon SpA
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary Objective: The primary objective of this study is to assess the tolerability and safety of two dose levels of aerosolized L-CsA vs placebo in addition to SoC therapy for BOS in adult allo-HSCT recipients. Secondary Objectives: The secondary objectives of this study are to assess PK and exploratory efficacy and quality of life of two dose levels of aerosolized L-CsA vs placebo in addition to SoC therapy for BOS in adult allo-HSCT recipients.

Description:

This is a Phase II prospective, multi-center, single-blind, randomized clinical trial evaluating safety and tolerability in adult recipients of an allo-HSCT with BOS. Twenty-four patients were planned for enrollment; but, at the time of the premature termination of this study, a total of 11 patients were screened for the study, of whom 5 patients did not fulfill the inclusion criteria and 6 patients were randomly allocated 1:1:1 in 3 treatment groups (L-CsA 10 mg + SoC, L-CsA 5 mg + SoC, or placebo + SoC). A total of 18 centers in 3 countries (France, Germany, and Spain) in Europe were initiated for this multi-center study. IMP was administered for up to 12 weeks treatment period. With low patient recruitment, the BOSTON-4 safety and tolerability study was terminated early by the sponsor on 18 March 2022. This decision was made after a careful and due diligent analysis performed by Zambon of the study status and considering the impact of coronavirus disease 2019 (COVID-19) pandemic on sites activities. From the beginning of the study, in December 2019, only 6 patients were randomized. So it was estimated that continuing the trial with the current protocol and setting would have taken another 9 years for the study to complete.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 6
• Est. completion date: December 15, 2022
• Est. primary completion date: June 16, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age >/= 18 years

2. Patient must have a history of allogeneic HSCT, regardless of source of stem cell or donor or indication for allogeneic HSCT

3. Documented diagnosis of chronic Graft versus Host Disease (cGvHD) in any organ other than the lung. If BOS is the only manifestation of cGvHD, lung biopsy must have been performed before entering the trial to confirm BOS diagnosis.

4. Confirmed diagnosis of BOS Score 1 [Jagasia et al. 2015] within > 6 months and < 3 years after allo-HSCT: FEV1/FVC < 0.7 at Screening Visit AND Post-bronchodilator FEV1 >/= 60 and = 79% predicted at Screening Visit AND

• 10% decline of FEV1 % predicted within 24 months prior to Screening Visit AND Absence of acute infection in the respiratory tract.

5. Patient must be capable of understanding the purposes and risks of the study, has given written informed consent, and agrees to comply with the study requirements.

6. Patient is capable of aerosol inhalation.

7. Women of childbearing potential must have a negative serum or urine pregnancy test at screening and at randomization visit.

Exclusion Criteria:

1. Active bacterial, viral (as confirmed by multiplex PCR) or fungal infection not successfully resolved at least 4 weeks prior to the Screening Visit.

2. Chronic renal dysfunction with serum creatinine >/= 2.5 mg/dL or need for renal dialysis.

3. Chronic hepatic dysfunction with serum total bilirubin > 5x upper limit of normal (ULN), transaminases > 5x ULN, or alkaline phosphatase > 5x ULN.

4. Evidence of relapse of the primary malignancy which warranted allogeneic bone marrow transplant.

5. Use of azithromycin within 4 weeks prior to Randomization (Visit 1).

6. Use of zafirlukast during the study period.

7. Chronic oxygen use or use of non-invasive ventilation.

8. Active smokers (i.e. any kind of inhaled nicotine consumption).

9. Pregnant women or women who are unwilling to use appropriate birth control to avoid pregnancy over the course of the clinical trial.

10. Women who are currently breastfeeding.

11. Known hypersensitivity to L-CsA or to cyclosporine A.

12. Patients who do not tolerate administration of inhaled bronchodilators (e.g., salbutamol).

13. Patients with life-expectancy of less than 6 months.

14. Treatments with other Investigational Medicinal Products (IMPs) or previous therapies within four weeks or five times half-life of the drug, whichever is longer prior to screening and during the study. Participation in registries, considering the before, is allowed.

15. Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary procedures.

16. Any co-existing medical condition that in the Investigator's judgment will substantially increase the risk associated with the patient's participation in the clinical trial.

17. Pre-scheduled hospitalizations, surgeries or interventions planned to be performed after obtaining Informed Consent for this study.

Related Conditions & MeSH terms

• Bronchiolitis
• Bronchiolitis Obliterans
• Bronchiolitis Obliterans Syndrome
• Bronchiolitis Obliterans Syndrome (BOS)
• GVHD, Chronic
• Stem Cell Transplant Complications
• Syndrome

Intervention

Drug:
• Liposomal Cyclosporine A
Liposomal Cyclosporine A is administered at different dosages in the first two arms (10 mg bid and 5 mg bid, respectively) with a new technology of nebulizing liquid drugs, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 µm
• Liposomal Placebo
Liposomal Placebo is administered with the same new technology of nebulizing liquid drugs used for L-CsA, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 µm

Locations

Country	Name	City	State
France	CHU Hôpital Sud	Amiens
France	Centre Hospitalier Universitaire d'Angers	Angers
France	Centre Hospitalier Universitaire Grenoble Alpes - Hopital Albert Michallon	La Tronche
France	Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez	Lille
France	CHU de Nancy, Hopital Brabois	Nancy
France	CHU de Nantes - Hotel-Dieu	Nantes
France	Hopital Saint Louis	Paris
France	CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque	Pessac
Germany	St.-Johannes-Hospital	Dortmund
Germany	Universitätsklinikum Carl Gustav Carus	Dresden
Germany	Universitätsklinikum Köln	Köln
Germany	Universitätsklinikum Münster	Münster
Spain	Hospital Clinic i Provincial	Barcelona
Spain	Hospital de la Santa Creu i Sant Pau	Barcelona
Spain	Hospital Universitario Ramón y Cajal	Madrid
Spain	Hospital Clinico Universitario de Valencia	Valencia
Spain	Hospital Universitari i Politècnic La Fe	Valencia

Sponsors (1)

Lead Sponsor	Collaborator
Zambon SpA

Countries where clinical trial is conducted

France,  Germany,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Local Tolerability Events of Interest From Baseline to Visit 3 (Week 4)	The local tolerability events of interest taken into consideration were: Cough, Wheezing, Bronchospasm, Throat irritation and Change from baseline in FEV1 to Visit 3.	at Week 4 (visit 3)
Primary	Number of Participants With AE and sAE of Different Level of Severity During the First 4 Weeks of Treatment	An adverse event (AE) is any untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.; A serious adverse event is an adverse event that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect.	During the first 4 weeks of treatment
Secondary	Number of Local Tolerability Events of Interest From Baseline to Week 12	The local tolerability events of interest taken into consideration were: Cough, Wheezing, Bronchospasm, Throat irritation and Change from baseline in FEV1 to Visit 3.	at Week 12
Secondary	Number of Participants With AE and sAE of Different Level of Severity During the First 12 Weeks of Treatment	An adverse event (AE) is any untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.; A serious adverse event is an adverse event that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect.	During the first 12 weeks of treatment
Secondary	CsA Whole Blood Concentrations and CsA Whole Blood Trough Levels	Whole Blood concentrations (Week 0) are at pre-dose, directly after end of inhalation, 15, 30, and 45 minutes, and 1, 1.5, 2, and 4 hours after end of inhalation, and whole blood trough levels (CsA concentration) at Weeks 2, 4, 8, and 12 were calculated.	Weeks 0 (pre-dose, directly after end of inhalation, 15, 30, 45, 60 min, 1.5 h, 2h, 4h), 2, 4, 8, and 12